Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
This network meta-analysis evaluated multiple interventions for pediatric atopic dermatitis, including dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D. The analysis included 3961 children and assessed outcomes such as SCORAD and EASI scores. The authors used the CINeMA tool to grade certainty of evidence and risk of bias 2.0 to assess bias.
Dupilumab demonstrated a cumulative probability ranking of 96.0% for SCORAD improvement. It was found to be more effective than melatonin, probiotics, SCG, synbiotic, and vitamin D. For EASI scores, pimecrolimus, dupilumab, and nemolizumab were superior to probiotics. Pimecrolimus showed a cumulative probability ranking of 99.9%.
The authors note that adverse events, serious adverse events, discontinuations, and tolerability were not reported. The practice relevance suggests these treatments show potential as favorable options for managing pediatric atopic dermatitis. The study does not establish causation for all associations and relies on data from the included network meta-analysis.